Wanbury Clarifies Zero Impact on FY27 Guidance and Operations Following Investor Queries
Wanbury Ltd 路 Press Release 路 16 Nov 2026, 8:23 pm
Wanbury Clarifies Zero Impact on FY27 Guidance and Operations Following Investor Queries Wanbury confirmed its business and sales remain unaffected, with US market exposure via its Tanuku facility representing approximately 6% of consolidated YTD revenue. New ANDAs and regulatory filings will be transitioned to the Patalganga API manufacturing facility, which is US FDA-approved with zero observations from its last inspection and operating normally. Based on current assessments, the company reiterated that there is no impact on operations or its financial guidance for FY'27.
Original exchange filing (PDF)
More announcements from Wanbury Ltd
- Disclosure under Regulation 30 of the SEBI LODR, 2015 - Investors Presentation on Q2 and Half Year ended 30.09.2026. 路 18 Nov 2026
- Wanbury Limited''s Tanuku Plant - US FDA Inspection - Updates 路 16 Nov 2026
- Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HC1 EP grade. 路 12 Nov 2026
- Press Release on Standalone and Consolidated Un-audited Financial Results for the second quarter & half year ended 30th September, 2026. 路 06 Nov 2026
- Financial Results as on 30th September, 2026 路 05 Nov 2026
- Outcome of the Board Meeting held on November 04, 2026 路 05 Nov 2026
- Wanbury Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
- Wanbury Limited receives Australian TGA GMP Compliance Certificate for its Tanuku Plant, Strengthening Its Global Pharmaceutical Manufacturing Credentials. 路 30 Oct 2026
